Long Term Prophylactic Therapy of Congenital Long QT Syndrome Type III (LQT3) With Ranolazine

Who is this study for? Patients with long QT syndrome type 3
Status: Unknown status
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

The purpose of this study is to determine whether ranolazine will reduce the risk of arrhythmic events in patients with long QT syndrome type 3.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: No
View:

• Long QT patients with genetic confirmation of carrier-status for the D1790G mutation in the SCN5A gene

• Corrected QT interval > 460 msec

Locations
Other Locations
Israel
Tel Aviv Medical Center
Recruiting
Tel Aviv
Contact Information
Primary
Sami Viskin, MD
samiviskin@gmail.com
972-3-6973311
Backup
Jesaia Benhorin, MD
972-3-6973311
Time Frame
Start Date: October 2012
Completion Date: November 2017
Participants
Target number of participants: 10
Treatments
Experimental: Ranolazine
Ranolazine 500-1000 mg twice a day as tolerated
Sponsors
Leads: Tel-Aviv Sourasky Medical Center

This content was sourced from clinicaltrials.gov

Similar Clinical Trials